Amolyt KOL Event on Eneboparatide: A PTHR1 Agonist for Hypoparathyroidism
About The Event
Join us in-person or virtually for a KOL event hosted by Amolyt Pharma, featuring Aliya Khan, MD, FRCPC, FACP, FACE, FASBMR (McMaster University Medical Centre) who will discuss the unmet medical need and current treatment landscape for patients suffering from hypoparathyroidism and Amolyt’s potential treatment solution with eneboparatide, a parathyroid hormone receptor 1 (PTHR1) agonist with a novel mechanism of action.
Patty Keating, patient and Chairwoman of the Hypoparathyroidism Association, will also discuss her personal experience living with the disease, and challenges with the current standard of care.
Mark Sumeray, MD, chief medical officer at Amolyt Pharma, will provide an update on the Calypso study, a Phase 3 clinical trial of eneboparatide for the treatment of patients with hypoparathyroidism.
A live question and answer session will follow the formal presentations.